These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). Gurumurthy M; Bryant A; Shanbhag S Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD006912. PubMed ID: 24753008 [TBL] [Abstract][Full Text] [Related]
6. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Kokka F; Bryant A; Brockbank E; Powell M; Oram D Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525 [TBL] [Abstract][Full Text] [Related]
7. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Lawrie TA; Nordin A; Chakrabarti M; Bryant A; Kaushik S; Pepas L Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011837. PubMed ID: 26728940 [TBL] [Abstract][Full Text] [Related]
8. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Ang C; Chan KK; Bryant A; Naik R; Dickinson HO Cochrane Database Syst Rev; 2011 Apr; (4):CD007697. PubMed ID: 21491400 [TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910 [TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcome measures for follow-up after gynaecological cancer treatment. Nama V; Nordin A; Bryant A Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD010299. PubMed ID: 24249483 [TBL] [Abstract][Full Text] [Related]
12. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Kew F; Galaal K; Bryant A; Naik R Cochrane Database Syst Rev; 2011 Jun; (6):CD006119. PubMed ID: 21678351 [TBL] [Abstract][Full Text] [Related]
14. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer. Lawal AO; Musekiwa A; Grobler L Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789 [TBL] [Abstract][Full Text] [Related]
15. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Kucukmetin A; Naik R; Galaal K; Bryant A; Dickinson HO Cochrane Database Syst Rev; 2010 Jul; 2010(7):CD007792. PubMed ID: 20614464 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Winter-Roach BA; Kitchener HC; Dickinson HO Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239 [TBL] [Abstract][Full Text] [Related]
17. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421 [TBL] [Abstract][Full Text] [Related]
18. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care. Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Winter-Roach BA; Kitchener HC; Lawrie TA Cochrane Database Syst Rev; 2012 Mar; 3(3):CD004706. PubMed ID: 22419298 [TBL] [Abstract][Full Text] [Related]
20. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. Wuntakal R; Seshadri S; Montes A; Lane G Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]